R&D Systems™ Recombinant Human VEGF 165 Protein : 50 µg, Lyophilisé à partir d’une solution filtrée à 0,2 µm dans l’acétonitrile et le TFA avec du tréhalose.

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity

Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1323. The ED50 for this effect is 1-6 ng/mL. The specific activity of recombinant human VEGF165 is approximately 1.7 x 103 U/μg, which is calibrated against recombinant human VEGF165 WHO Standard (NIBSC code: 02/286). Specific activity is for reference purposes only and is not routinely tested.

Proprieties :

Formule : Lyophilisé à partir d’une solution filtrée à 0,2 μm dans l’acétonitrile et le TFA avec du tréhalose.
Poids moléculaire : 20-22 kDa, under reducing conditions. 39-42 kDa, under non-reducing conditions.
Nom :  VEGF 165
Source : Spodoptera frugiperda,Sf 21 (baculovirus)-derived human VEGF protein Ala27-Arg191
Conditions de stockage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution.
Forme structurelle : Disulfide-linked homodimer
Reconstitution : Reconstitute at 100 μg/mL in sterile PBS. Alternatively, reconstitute (at 100-500 μg/mL in sterile 4 mM HCl.)
Pureté : 97%, by SDS-PAGE with silver staining.